4.1 Review

Lithium for bipolar disorder: a review of the recent literature

期刊

EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 14, 期 9, 页码 1079-1098

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2014.947965

关键词

bipolar disorder; dosing; efficacy; lithium; predictors of response; suicide

资金

  1. Cephalon
  2. Eli Lilly
  3. GlaxoSmithKline
  4. Janssen-Ortho
  5. Pfizer
  6. Roche
  7. Servier
  8. Wyeth
  9. AstraZeneca
  10. Lundbeck
  11. RANZCP
  12. New South Wales Institute of Psychiatry
  13. MIGA

向作者/读者索取更多资源

Lithium is a commonly prescribed treatment for bipolar disorder. Many early studies on which its use has been historically based no longer meet current research standards. A large number of studies with more modern designs have been recently published warranting a review. New research adds to the evidence for lithium's efficacy in mania and maintenance. There is also additional evidence, albeit less robust, to support its benefit in bipolar depression and mixed episodes. Meta-analyses of mainly observational data have found reduced suicidal behavior in bipolar patients taking lithium. Careful monitoring and prescribing can reduce the risk of adverse effects.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据